The PCDx test provides patients and physicians with a blueprint of the underlying mechanisms of a patient’s disease, potential treatment approaches, and comprehensive inventory of relevant clinical trials. It identifies actionable classes of genomic alterations in hundreds of cancer-related genes, including:
Changes in the DNA sequence of chromosomes, including insertions, deletions and base substitutions. Somatic mutation analysis has become standard of practice for solid tumors in order to identify therapeutic sensitizing and resistance mutations (e.g., EGFR, KRAS, BRAF).
Copy Number Variations (CNV)
Tumor Mutation Burden
TMB is to look at the rate of mutations with the assumption that more mutations increase likelihood of an immunogenic mutation being present. The larger a region is sequenced, the more accurate TMB is. Immunotherapy pharmaceutical companies recommend at least 0.7 million bases for accurately detecting TMB. PCDx sequences ~1 million bases: Well above Pharma comanies recommendation.
THE PCDx ADVANTAGE
PCDx is Fast
Paradigm promises a clinically relevant turnaround time. Customers can expect 5 business days from sample receipt to reporting ensures continuity of clinical care.
PCDx is Accurate
Comprehensive NGS results on as little as 1-2 slides (+ 1 slide for H&E + 1 slide per IHC)
PCDx is Effective
Looks at biomarkers associated with >90 FDA approved therapies and 24 combinations.
Paradigm brings cutting-edge diagnostics and biomarker driven clinical trials to benefit cancer patients.
Through Next-Gen Sequencing (NGS), and other biomarker analysis, the Paradigm Cancer Diagnostic (PCDx) test is able to provide the treating clinician with information about the genomic and proteomic landscape of a patient’s cancer, helping personalize each patient’s course of treatment.